WEBULL
WebtradeDownload

Absci (ABSI) Maps Out Phase 2 Trial, Is It Still 29% Undervalued?

Simply Wall St · 1d ago

Absci (ABSI) has put ABS-201 for endometriosis in sharper focus, outlining plans for a global Phase 2 STORYLINE trial that has turned attention back to the stock’s AI-driven drug pipeline.

Absci’s latest ABS-201 update lands after a volatile run, with the share price returning 21.21% over the past week and 169.94% year to date, while total shareholder return over three years is very large at around 7x. This suggests strong but jumpy momentum tied to pipeline and partnership headlines.

Scan beyond Absci and compare this AI-driven pipeline story with other clinically focused biotechs on the 38 healthcare AI stocks to see how the market is pricing similar momentum.

For Absci, the recent spike raises a simple tension. Are investors now paying more for clear progress in ABS-201 and the wider AI-powered pipeline, or has sentiment sprinted ahead of what the current fundamentals support as reflected in today’s valuation?

Most Popular Narrative: 29% Undervalued

Compared with Absci's last close of $9.75, the most followed narrative fair value of about $13.78 points to a sizeable valuation gap that the market is still debating.

Advancement of ABS-201 toward two proof of concept readouts in androgenetic alopecia and endometriosis over the next 24 months is described as positioning Absci to convert large underpenetrated markets into meaningful revenue growth and improved earnings power.

See why 11 investors see Absci as 29% undervalued.

Result: Fair Value of $13.78 (UNDERVALUED)

Still, Absci’s story rests heavily on ABS-201 clearing early efficacy and safety hurdles, and on the company turning minimal current revenue into something more substantial.

Find out about the key risks to this Absci narrative.

Next Steps

Mixed feelings about Absci's surge and risks so far. Move quickly, review the underlying data, and weigh the 1 key reward and 3 important warning signs.

Looking for more ideas beyond Absci?

If Absci has sharpened your interest, do not stop here. Use the Simply Wall Street screener to surface other opportunities before they move without you.

  • Target steady cash generators by scanning companies with robust income streams and strong balance sheets using the 7 dividend fortresses.
  • Hunt for mispriced quality by filtering for businesses that combine sound fundamentals with valuations that still look appealing through the 30 high quality undervalued stocks.
  • Spot resilient opportunities by finding companies with lower risk profiles that may help smooth out portfolio swings using the 31 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.